Literature DB >> 12206789

Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy?

Giuliana Ferrari1, Fulvio Mavilio.   

Abstract

Differentiated muscle fibres can be formed by transplanted haematopoietic stem cells in models of acute or chronic muscle regeneration, including the dystrophin-deficient mdx mouse. Muscle-forming activity can be found in adult, foetal and embryonic haematopoietic tissues. The blood-to-muscle transition may be due to transdifferentiation of haematopoietic progenitors in response to local signals provided by the regenerating muscle. These signals are only poorly provided by the muscle of the mdx mouse, since transplantation into these mice of normal C57Bl/6 bone marrow gives rise only to a minimal number of muscle fibres expressing the normal dystrophin protein (<1%) throughout the animal life span. Expansion and active recruitment to myogenic differentiation of transplanted haematopoietic cells are therefore critical factors for a future use of bone marrow transplantation in cell/gene therapy of muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206789     DOI: 10.1016/s0960-8966(02)00102-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

1.  Regulation of osteogenic differentiation of rat bone marrow stromal cells on 2D nanorod substrates.

Authors:  Gagandeep Kaur; Mani T Valarmathi; Jay D Potts; Esmaiel Jabbari; Tara Sabo-Attwood; Qian Wang
Journal:  Biomaterials       Date:  2009-12-22       Impact factor: 12.479

2.  Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges.

Authors:  Sujata Law; Samaresh Chaudhuri
Journal:  Am J Stem Cells       Date:  2013-03-08

3.  Mesenchymal stem cells are recruited to striated muscle by NFAT/IL-4-mediated cell fusion.

Authors:  Manja Schulze; Fikru Belema-Bedada; Antje Technau; Thomas Braun
Journal:  Genes Dev       Date:  2005-08-01       Impact factor: 11.361

4.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.

Authors:  Bàrbara Flix; Xavier Suárez-Calvet; Jordi Díaz-Manera; Eva Santos-Nogueira; Renzo Mancuso; Jordi Barquinero; Miquel Navas; Xavier Navarro; Isabel Illa; Eduard Gallardo
Journal:  Stem Cells Dev       Date:  2013-07-26       Impact factor: 3.272

Review 5.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04

6.  Hematopoietic cell transplantation directly into dystrophic muscle fails to reconstitute satellite cells and myofibers.

Authors:  Christian S Kuhr; Marilena Lupu; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2007-06-18       Impact factor: 5.742

Review 7.  Tissue engineering in urology: where are we going?

Authors:  Adam R Metwalli; James R Colvert; Bradley P Kropp
Journal:  Curr Urol Rep       Date:  2003-04       Impact factor: 2.862

8.  Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy - a case report.

Authors:  Alok Sharma; Hemangi Sane; Amruta Paranjape; Khushboo Bhagawanani; Nandini Gokulchandran; Prerna Badhe
Journal:  Am J Case Rep       Date:  2014-03-28

9.  Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells.

Authors:  Neia Naldaiz-Gastesi; María Goicoechea; Sonia Alonso-Martín; Ana Aiastui; Macarena López-Mayorga; Paula García-Belda; Jaione Lacalle; Carlos San José; Marcos J Araúzo-Bravo; Lidwine Trouilh; Véronique Anton-Leberre; Diego Herrero; Ander Matheu; Antonio Bernad; José Manuel García-Verdugo; Jaime J Carvajal; Frédéric Relaix; Adolfo Lopez de Munain; Patricia García-Parra; Ander Izeta
Journal:  Stem Cell Reports       Date:  2016-09-01       Impact factor: 7.765

10.  Leucocyte and Platelet-rich Fibrin: a carrier of autologous multipotent cells for regenerative medicine.

Authors:  Rosa Di Liddo; Thomas Bertalot; Alessio Borean; Ivan Pirola; Alberto Argentoni; Sandra Schrenk; Carola Cenzi; Stefano Capelli; Maria Teresa Conconi; Pier Paolo Parnigotto
Journal:  J Cell Mol Med       Date:  2018-01-05       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.